Day: September 21, 2024

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 to dateTEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749...

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPs New data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified New ADVANCE survey findings highlight key patient-reported reasons for accepting long-acting injectable treatment options, including improvement of symptoms/condition, recommendation by a HCP, and ease of use dataTEL AVIV, Israel and PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),...